Total Payments
$172,626
2024 Payments
$1,006
Companies
12
Transactions
401
Medicare Patients
4,081
Medicare Billing
$850,648
Payment Breakdown by Category
Other$142,314 (82.4%)
Food & Beverage$14,556 (8.4%)
Travel$8,834 (5.1%)
Consulting$6,744 (3.9%)
Education$179.07 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $142,314 | 87 | 82.4% |
| Food and Beverage | $14,556 | 206 | 8.4% |
| Travel and Lodging | $8,834 | 98 | 5.1% |
| Consulting Fee | $6,744 | 5 | 3.9% |
| Education | $179.07 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $88,636 | 155 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26,730 | 69 | $0 (2024) |
| ABBVIE INC. | $25,090 | 68 | $0 (2022) |
| Lilly USA, LLC | $16,309 | 46 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $13,936 | 23 | $0 (2017) |
| Dexcom, Inc. | $1,370 | 28 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $275.69 | 4 | $0 (2020) |
| Amgen Inc. | $135.81 | 2 | $0 (2019) |
| Abbott Laboratories | $74.31 | 3 | $0 (2021) |
| Becton, Dickinson and Company | $25.78 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,006 | 17 | Lilly USA, LLC ($307.36) |
| 2023 | $1,276 | 20 | Novo Nordisk Inc ($668.88) |
| 2022 | $14,950 | 38 | Novo Nordisk Inc ($14,336) |
| 2021 | $12,311 | 28 | Novo Nordisk Inc ($10,414) |
| 2020 | $16,626 | 38 | Novo Nordisk Inc ($8,737) |
| 2019 | $27,936 | 67 | Novo Nordisk Inc ($10,127) |
| 2018 | $48,358 | 90 | Novo Nordisk Inc ($23,363) |
| 2017 | $50,164 | 103 | Novo Nordisk Inc ($20,712) |
All Payment Transactions
401 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Diabetes | ||||||
| 10/28/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $137.16 | General |
| Category: Endocrinology | ||||||
| 10/22/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $121.36 | General |
| Category: DIABETES | ||||||
| 10/01/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Endocrinology | ||||||
| 08/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $95.18 | General |
| 08/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $22.50 | General |
| 07/31/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $124.45 | General |
| Category: Obesity | ||||||
| 07/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: DIABETES | ||||||
| 05/28/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Diabetes | ||||||
| 05/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 05/21/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $33.73 | General |
| Category: Diabetes | ||||||
| 03/27/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Diabetes | ||||||
| 03/06/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $83.85 | General |
| 02/21/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $124.27 | General |
| Category: Diabetes | ||||||
| 01/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $7.35 | General |
| Category: DIABETES | ||||||
| 01/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Diabetes | ||||||
| 11/16/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 11/15/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $123.46 | General |
| 11/08/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: Diabetes | ||||||
| 09/21/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Endocrinology | ||||||
| 08/31/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $91.59 | General |
| Category: DIABETES | ||||||
| 08/25/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Diabetes | ||||||
| 08/09/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: Diabetes | ||||||
| 07/05/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $123.25 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 1,084 | 11,508 | $555,330 | $265,165 |
| 2022 | 11 | 1,150 | 10,003 | $512,904 | $226,483 |
| 2021 | 10 | 916 | 8,224 | $436,757 | $193,473 |
| 2020 | 9 | 931 | 7,246 | $417,808 | $165,527 |
Total Patients
4,081
Total Services
36,981
Medicare Billing
$850,648
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 101 | 10,200 | $367,200 | $186,120 | 50.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 504 | 671 | $130,174 | $61,931 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $14,617 | $6,390 | 43.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 59 | $8,555 | $3,873 | 45.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 56 | 88 | $10,648 | $2,447 | 23.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 97 | 150 | $10,500 | $1,794 | 17.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 125 | 147 | $8,526 | $1,391 | 16.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 139 | 146 | $5,110 | $1,219 | 23.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 83 | 8,580 | $304,560 | $142,326 | 46.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 511 | 693 | $134,442 | $62,651 | 46.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 70 | 70 | $21,770 | $8,539 | 39.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 50 | $7,250 | $3,042 | 42.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 48 | 79 | $9,559 | $2,154 | 22.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 85 | 154 | $10,780 | $1,868 | 17.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $2,948 | $1,698 | 57.6% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 136 | 168 | $9,744 | $1,613 | 16.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $3,048 | $1,289 | 42.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $2,748 | $797.23 | 29.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 163 | 173 | $6,055 | $505.20 | 8.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 74 | 7,020 | $250,560 | $113,058 | 45.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 461 | 663 | $128,622 | $63,419 | 49.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 52 | 52 | $16,172 | $6,464 | 40.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 59 | $8,555 | $3,539 | 41.4% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 38 | 72 | $8,712 | $2,076 | 23.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $3,810 | $1,634 | 42.9% |
About Dr. William Bayer, MD
Dr. William Bayer, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Carol Stream, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528162898.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Bayer, MD has received a total of $172,626 in payments from pharmaceutical and medical device companies, with $1,006 received in 2024. These payments were reported across 401 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($142,314).
As a Medicare-enrolled provider, Bayer has provided services to 4,081 Medicare beneficiaries, totaling 36,981 services with total Medicare billing of $850,648. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Carol Stream, IL
- Active Since 09/08/2006
- Last Updated 03/25/2015
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1528162898
Products in Payments
- JARDIANCE (Drug) $42,230
- Synthroid (Drug) $17,929
- Ozempic (Drug) $16,946
- Tresiba (Drug) $13,835
- RYBELSUS (Drug) $12,265
- Rybelsus (Drug) $11,556
- Victoza (Drug) $10,112
- SOLIQUA (Drug) $8,837
- Xultophy 100/3.6 (Drug) $7,939
- TOUJEO (Drug) $5,099
- SYNTHROID (Drug) $3,004
- Dexcom G6 Transmitter (Medical Supply) $514.85
- MOUNJARO (Drug) $433.07
- Dexcom CGM (Device) $276.73
- FARXIGA (Drug) $275.69
- DEXCOM CGM (Device) $269.31
- Xultophy (Drug) $220.00
- Dexcom G5 Mobile CGM System (Device) $190.67
- Levemir (Drug) $143.00
- TRULICITY (Drug) $129.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.